ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer
- Citation:
- J Clin Oncol vol 31 (15 suppl) abstr 502
- Meeting Instance:
- ASCO 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2026
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- A. Buzdar V. Suman F. Meric-Bernstam M. Leitch M. Ellis J. Boughey G. Unzeitig M. Royce K. Hunt
- Networks:
- Study
- ACOSOG-Z1041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: